AIDS_2026_ OAX1106LB

Title: Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Versus Daily Standard-of-Care Therapy in Virologically Suppressed Adults With HIV-1: Week 48 Results of the ISLEND-2 Phase 3 Trial

Author: Amy E. Colson

Oral Presentation

Graphical Summary

For information related to the ISLEND-1​ study, please see oral OAB1406LB

Email Presentation

Share this information

Enter the information below to send this data to a friend or collegue.